PEGylated d-serine dehydratase as a d-serine reducing agent

Tomokazu Ito, Hiroe Takada, Keiko Isobe, Masataka Suzuki, Yasuyuki Kitaura, Hisashi Hemmi, Tsukasa Matsuda, Jumpei Sasabe, Tohru Yoshimura

Research output: Contribution to journalArticle

Abstract

D-Serine is an endogenous coagonist for N-methyl-. d-aspartate (NMDA) receptors and is involved in excitatory neurotransmission. Excessive receptor activation causes excitotoxicity, leading to various acute and chronic neurological disorders. Decrease in d-serine content may provide a therapeutic strategy for the treatment of the neurological disorders in which overstimulation of NMDA receptors plays a pathological role. Saccharomyces cerevisiae d-serine dehydratase (Dsd1p), which acts dominantly on d-serine, may be a useful d-serine reducing agent. We conjugated a linear 5-kDa polyethylene glycol (PEG) to Dsd1p (PEG-Dsd1p) and examined the effects of PEG-conjugation on its biochemical and pharmacokinetic properties. PEG-Dsd1p retained activity, specificity, and stability of the enzyme. The PEG modification extended the serum half-life of Dsd1p in mice 6-fold, from 3.8. h to 22.4. h. PEG-Dsd1p was much less immunogenic compared to the unmodified enzyme. Intraperitoneal administration of PEG-Dsd1p was effective in decreasing the d-serine content in the mouse hippocampus. These findings suggest that PEG-Dsd1p may be a novel tool for lowering d-serine levels in vivo.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume116
DOIs
Publication statusPublished - 2014 Oct 9

Fingerprint

L-Serine Dehydratase
Reducing Agents
Serine
Nervous System Diseases
N-Methyl-D-Aspartate Receptors
Enzyme Stability
Pharmacokinetics
Enzymes
Aspartic Acid
Synaptic Transmission
Yeast
Half-Life
Saccharomyces cerevisiae
Hippocampus
Chemical activation

Keywords

  • D-amino acid
  • D-serine
  • D-serine dehydratase
  • NMDA receptors
  • PEGylation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Spectroscopy
  • Clinical Biochemistry

Cite this

Ito, T., Takada, H., Isobe, K., Suzuki, M., Kitaura, Y., Hemmi, H., ... Yoshimura, T. (2014). PEGylated d-serine dehydratase as a d-serine reducing agent. Journal of Pharmaceutical and Biomedical Analysis, 116, 34-39. https://doi.org/10.1016/j.jpba.2014.12.044

PEGylated d-serine dehydratase as a d-serine reducing agent. / Ito, Tomokazu; Takada, Hiroe; Isobe, Keiko; Suzuki, Masataka; Kitaura, Yasuyuki; Hemmi, Hisashi; Matsuda, Tsukasa; Sasabe, Jumpei; Yoshimura, Tohru.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 116, 09.10.2014, p. 34-39.

Research output: Contribution to journalArticle

Ito, T, Takada, H, Isobe, K, Suzuki, M, Kitaura, Y, Hemmi, H, Matsuda, T, Sasabe, J & Yoshimura, T 2014, 'PEGylated d-serine dehydratase as a d-serine reducing agent', Journal of Pharmaceutical and Biomedical Analysis, vol. 116, pp. 34-39. https://doi.org/10.1016/j.jpba.2014.12.044
Ito, Tomokazu ; Takada, Hiroe ; Isobe, Keiko ; Suzuki, Masataka ; Kitaura, Yasuyuki ; Hemmi, Hisashi ; Matsuda, Tsukasa ; Sasabe, Jumpei ; Yoshimura, Tohru. / PEGylated d-serine dehydratase as a d-serine reducing agent. In: Journal of Pharmaceutical and Biomedical Analysis. 2014 ; Vol. 116. pp. 34-39.
@article{68991e2b9d1f48cd949b8154b55c8745,
title = "PEGylated d-serine dehydratase as a d-serine reducing agent",
abstract = "D-Serine is an endogenous coagonist for N-methyl-. d-aspartate (NMDA) receptors and is involved in excitatory neurotransmission. Excessive receptor activation causes excitotoxicity, leading to various acute and chronic neurological disorders. Decrease in d-serine content may provide a therapeutic strategy for the treatment of the neurological disorders in which overstimulation of NMDA receptors plays a pathological role. Saccharomyces cerevisiae d-serine dehydratase (Dsd1p), which acts dominantly on d-serine, may be a useful d-serine reducing agent. We conjugated a linear 5-kDa polyethylene glycol (PEG) to Dsd1p (PEG-Dsd1p) and examined the effects of PEG-conjugation on its biochemical and pharmacokinetic properties. PEG-Dsd1p retained activity, specificity, and stability of the enzyme. The PEG modification extended the serum half-life of Dsd1p in mice 6-fold, from 3.8. h to 22.4. h. PEG-Dsd1p was much less immunogenic compared to the unmodified enzyme. Intraperitoneal administration of PEG-Dsd1p was effective in decreasing the d-serine content in the mouse hippocampus. These findings suggest that PEG-Dsd1p may be a novel tool for lowering d-serine levels in vivo.",
keywords = "D-amino acid, D-serine, D-serine dehydratase, NMDA receptors, PEGylation",
author = "Tomokazu Ito and Hiroe Takada and Keiko Isobe and Masataka Suzuki and Yasuyuki Kitaura and Hisashi Hemmi and Tsukasa Matsuda and Jumpei Sasabe and Tohru Yoshimura",
year = "2014",
month = "10",
day = "9",
doi = "10.1016/j.jpba.2014.12.044",
language = "English",
volume = "116",
pages = "34--39",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - PEGylated d-serine dehydratase as a d-serine reducing agent

AU - Ito, Tomokazu

AU - Takada, Hiroe

AU - Isobe, Keiko

AU - Suzuki, Masataka

AU - Kitaura, Yasuyuki

AU - Hemmi, Hisashi

AU - Matsuda, Tsukasa

AU - Sasabe, Jumpei

AU - Yoshimura, Tohru

PY - 2014/10/9

Y1 - 2014/10/9

N2 - D-Serine is an endogenous coagonist for N-methyl-. d-aspartate (NMDA) receptors and is involved in excitatory neurotransmission. Excessive receptor activation causes excitotoxicity, leading to various acute and chronic neurological disorders. Decrease in d-serine content may provide a therapeutic strategy for the treatment of the neurological disorders in which overstimulation of NMDA receptors plays a pathological role. Saccharomyces cerevisiae d-serine dehydratase (Dsd1p), which acts dominantly on d-serine, may be a useful d-serine reducing agent. We conjugated a linear 5-kDa polyethylene glycol (PEG) to Dsd1p (PEG-Dsd1p) and examined the effects of PEG-conjugation on its biochemical and pharmacokinetic properties. PEG-Dsd1p retained activity, specificity, and stability of the enzyme. The PEG modification extended the serum half-life of Dsd1p in mice 6-fold, from 3.8. h to 22.4. h. PEG-Dsd1p was much less immunogenic compared to the unmodified enzyme. Intraperitoneal administration of PEG-Dsd1p was effective in decreasing the d-serine content in the mouse hippocampus. These findings suggest that PEG-Dsd1p may be a novel tool for lowering d-serine levels in vivo.

AB - D-Serine is an endogenous coagonist for N-methyl-. d-aspartate (NMDA) receptors and is involved in excitatory neurotransmission. Excessive receptor activation causes excitotoxicity, leading to various acute and chronic neurological disorders. Decrease in d-serine content may provide a therapeutic strategy for the treatment of the neurological disorders in which overstimulation of NMDA receptors plays a pathological role. Saccharomyces cerevisiae d-serine dehydratase (Dsd1p), which acts dominantly on d-serine, may be a useful d-serine reducing agent. We conjugated a linear 5-kDa polyethylene glycol (PEG) to Dsd1p (PEG-Dsd1p) and examined the effects of PEG-conjugation on its biochemical and pharmacokinetic properties. PEG-Dsd1p retained activity, specificity, and stability of the enzyme. The PEG modification extended the serum half-life of Dsd1p in mice 6-fold, from 3.8. h to 22.4. h. PEG-Dsd1p was much less immunogenic compared to the unmodified enzyme. Intraperitoneal administration of PEG-Dsd1p was effective in decreasing the d-serine content in the mouse hippocampus. These findings suggest that PEG-Dsd1p may be a novel tool for lowering d-serine levels in vivo.

KW - D-amino acid

KW - D-serine

KW - D-serine dehydratase

KW - NMDA receptors

KW - PEGylation

UR - http://www.scopus.com/inward/record.url?scp=84945461713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945461713&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2014.12.044

DO - 10.1016/j.jpba.2014.12.044

M3 - Article

C2 - 25617179

AN - SCOPUS:84945461713

VL - 116

SP - 34

EP - 39

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -